19 results about "Host genome" patented technology

The application provides a quality control for detecting respiratory pathogen nucleic acid, which comprises any one or more of the following respiratory pathogens: coronavirus, influenza virus, adenovirus, Mycoplasma pneumoniae, Streptococcus pneumoniae, rhinovirus or / and Legionella pneumophila. The full-length genome sequence of the coronavirus is divided into 6 target fragments, each with a length of 4000-5500 bp. The quality control of the application covers all detection target sequences (or target points) of the coronavirus, has a wide coverage, comprehensively detects target points, and does not have the phenomenon of missed detection. The quality control of the application contains main respiratory pathogen infections, has a wide range, and uses real virus samples and lentivirus samples as raw materials, and has more accurate detection target points. The preparation of the coronavirus quality control of the application integrates the target gene sequence into the host genome through the lentivirus vector, knocks out the self-replication gene in the preparation process, and has a "self-inactivation" ability, so that the recombinant lentivirus cannot replicate in the target cells and infect other cells.

The application discloses circular RNA and application thereof in pigeon trichomonad vaccine. The circular RNA comprises a coding element capable of encoding recombinant pigeon trichomonad AP33 or AP65 protein. The coding element has a sequence shown in SEQ ID NO. 1 or SEQ ID NO. 2 or a conservatively variant sequence thereof. The circular RNA can induce protein expression and generate high-level antibodies in an animal body. When the circular RNA is applied to the pigeon trichomonad vaccine, the circular RNA does not contain infectious worm component, can be degraded into nucleotides in the body, cannot be integrated into a host genome, has no risk for pigeons, can stimulate pigeons to generate a stronger immune response, including humoral immunity and cellular immunity, and can effectively resist parasitic infection. Meanwhile, the vaccine has high stability, the vaccine of the application can be prepared on a large scale through a molecular technology, and production cost is low.

Proteases of Group IV (+)ssRNA viruses were found to act on a human sequences in addition to the viral sequences. The identity of the cleavable human sequences is disclosed. Detection of these sequences can act as a diagnostic of infection. It is contemplated that these findings could be employed to facilitate post-translational silencing at the level of protein (e.g., removal of existing proteins), thus serving as a protein analog to CRISPR / Cas9 and RNAi / RISC, and further to enable sequence-specific silencing of host functions without the modification of the host genome.

The invention provides a genetic engineering strain, a construction method of the genetic engineering strain and application of the genetic engineering strain in biosynthesis of 5-hydroxytryptophan. According to the engineering bacterium, four key modules required by 5-HTP synthesis are sequentially introduced into a host genome in a genome integration mode through a CRISPR technology, and the four key modules comprise an aroGfbr-ppsA-tktA module for enhancing chorismate precursor supply, a trpEfbr-trpG module for catalyzing o-aminobenzoic acid generation, a salABCD gene cluster responsible for hydroxylating o-aminobenzoic acid into 5-hydroxy o-aminobenzoic acid, and a salABCD gene cluster responsible for hydroxylating 5-hydroxy o-aminobenzoic acid into 5-hydroxy o-aminobenzoic acid. And a trpDCBA module for converting the intermediate into the final product 5-HTP. The modules are respectively integrated into a plurality of non-essential gene regions, so that stable genetic expression is realized, and a complete metabolic pathway can be operated without plasmids or inducers. The strain can continuously accumulate 5-hydroxytryptophan (5-HTP) under a glucose fermentation condition, and has the advantages of simplicity and convenience in construction, high hereditary stability, low production cost, suitability for industrial-scale fermentation and the like.

The invention discloses a differential diagnosis and prognosis evaluation method for a pleural effusion microbiome based on metagenome sequencing and application, belongs to the technical field of bioinformatics, and discloses a method for analyzing the microbiome of a pleural effusion sample, and the method comprises the following steps: carrying out metagenome next-generation sequencing on an in-vitro pleural effusion sample to obtain a sequencing reading; performing bioinformatics analysis on the sequencing reading, and determining microorganism composition information of the pleural effusion sample based on a verification result; by establishing a unified mNGS experimental process and a parallel bioinformatics analysis path, two kinds of technical information of different dimensions, namely microbiome structural characteristics and host genome copy number variation (CNV), are synchronously output from single sequencing data, and the defect that microbiological analysis and genome analysis need to be carried out in batches in the prior art is overcome.

The application discloses a biological information-based genetic data mining system for Astragalus sinicus breeding, and particularly relates to the technical field of data mining; the system is characterized in that: raw sequencing data of a host genome of Astragalus sinicus and a symbiotic microorganism genome of rhizobium is collected and synchronized to generate a standardized genetic information dataset; sequence cross-contamination sites between the host genome and the symbiotic microorganism genome are identified, and genetic information interference from the microorganism is removed to obtain purified host genome data free of microorganism interference; the contribution of the microorganism genome to target traits of Astragalus sinicus is analyzed to obtain a microorganism effect weight; the purified host genome data and the microorganism effect weight are integrated to construct a trait association analysis model of Astragalus sinicus and locate trait association sites; finally, candidate breeding markers are screened based on the trait association site information to obtain a precise breeding genetic marker set; the application improves the accuracy and efficiency of Astragalus sinicus breeding.

The invention discloses a targeted sequencing method for helicobacter pylori multi-site drug-resistant gene mutation detection, and relates to the technical field, and the targeted sequencing method comprises the following steps: obtaining a clinical gastric mucosa sample, extracting and purifying mixed DNA of genome DNA containing helicobacter pylori 23S rRNA, gyrA and pbp1 drug-resistant genes and host genome DNA, and introducing a competitive internal standard into the purified mixed DNA; taking the competitive internal standard and the mixed DNA as templates, and carrying out a first round of multiple PCR amplification by virtue of a composite primer system, so as to obtain a first amplification product; purifying the first amplification product, carrying out solution hybridization capture by using a probe library, and washing by using a washing solution at a specific temperature to obtain an enriched product; taking the captured enriched product as a template, carrying out a second round of PCR amplification by using a primer carrying a complete sequencing joint, and constructing a sequencing library; according to the invention, high-accuracy synchronous detection and complex sample applicability of the helicobacter pylori multi-site drug-resistant gene can be effectively realized.

The invention discloses a transcription factor decoy short-chain DNA-Max protein complex and application thereof in preparation of a medicine for inhibiting colorectal cancer, and relates to the technical field of biology. The DNA-Max protein complex is composed of TCF / LEF TFD DNA and a Max protein complex, and the TCF / LEF TFD DNA is a transcription factor decoy short-chain DNA and can block combination of a TCF / LEF transcription factor and a downstream gene promoter of an original Wnt signal channel, so that the Wnt signal channel is blocked, tumor growth is inhibited, and the DNA-Max protein complex cannot be integrated to a host genome and is high in safety; the short-chain DNA sequence has a specific binding site with a delivery protein Max, and a targeted recognition protein for a colon cancer cell marker is added on the basis, so that the off-target risk is small, and a drug DNA molecule can be safely and efficiently delivered into a cell nucleus of a colon cancer cell in a targeted manner to play a role; the protein compound is natural macromolecules, does not contain other chemical elements, can be metabolized and absorbed by an organism, has small toxic and side effects, and can be applied to preparation of medicines for inhibiting colorectal cancer.

The application provides an IBS micro-ecological transplantation intelligent prediction method and system based on multi-omics driving, and relates to the field of biomedical technology. The method comprises the following steps: establishing a multi-omics data fusion subsystem to collect target patient metagenome, metabolome, host genome and clinical phenotype group data; inputting the data into a bacterial flora-metabolite joint network analysis model to construct an interaction network and extract features; generating a correlation matrix based on the features and host genome data and calculating an index; combining the clinical phenotype data and the index to generate an index through a dynamic response algorithm; and using a transfer learning framework to jointly model and output a therapeutic effect prediction result. The system comprises data acquisition, network analysis, correlation calculation, dynamic response and joint modeling modules. The application integrates multi-omics data, accurately mines the relationship between flora and host, realizes intelligent prediction of micro-ecological transplantation efficacy, provides strong support for IBS personalized treatment, and has data processing and security guarantee measures.

The invention discloses a bacterium multi-target non-specific genome engineering method and application thereof, and relates to the field of gene engineering. According to the invention, the MTI system is successfully expanded from eukaryotic cells to a prokaryotic bacterium system for the first time, the dependence on a long-segment specific attachment site (attB) is thoroughly eliminated in mechanism, and any pre-modified specific sequence does not need to be carried out on a host genome, so that real host-independent editing is realized. On the basis, a set of genome engineering platform which is simple and convenient to operate and universal is constructed, the platform supports stable integration of multi-copy and large-fragment DNA and is successfully applied to various bacteria including gram-positive bacteria and gram-negative bacteria, and the operable host range of genome engineering is greatly expanded.

The invention provides a CAR (chimeric antigen receptor) integration site detection method based on multiple amplification and long-read-long sequencing, and belongs to the technical field of cell and gene therapy, and the method comprises the following steps: carrying out PCR (polymerase chain reaction) amplification on sample DNA (deoxyribonucleic acid) by using a CAR specific primer to obtain an initial library; primarily screening the amplified fragments in the initial library, and reserving the amplified fragments with the length of more than or equal to 500bp to obtain a primarily selected library; performing third-generation sequencing on the amplified fragments in the primary selection library to obtain Raw FASTQ; further screening the amplified fragments in the Raw FASTQ, and retaining the amplified fragments simultaneously containing a CAR non-human primer binding region and an HA sequence to obtain a secondary selection library; and detecting the precise integration site of the CAR in the host genome. The method solves the technical problem that a traditional detection method is difficult to break through interference of a CAR homologous sequence, and provides safety guarantee for clinical transformation of gene editing cell therapy products such as CAR-T and the like.

The present invention relates to the field of biotechnology. More precisely, a genetic construct and method for producing a transgenic plant event, especially a sugarcane event {Saccharum spp.), which is resistant to infestation by the Diatraea saccharalis pest, popularly known as a pest, ordinary borer, reed borer or just borer is described. The invention describes the event, the methods for event identification as well as the insertion detection method based on the unique region of intersection between the insert and the host genome and the flanking regions that characterize it.

The application discloses an avian leukosis virus fluorescent quantitative PCR detection kit based on a pol gene and application thereof. The application is based on a fluorescent quantitative PCR technology, and specific primers and a TaqMan probe aiming at a pol gene conservative region of avian leukosis virus are designed to realize specific amplification and detection of virus nucleic acid. The core improvement of the application is that after nucleic acid is extracted from animal tissue, plasma and other samples, a DNA enzyme is added to perform digestion treatment, and residual host genome DNA in the sample is specifically degraded, so that a false positive problem caused by amplification of an endogenous pol gene is completely eliminated, and the specificity and accuracy of detection are obviously improved.

This invention discloses a method and apparatus for mining viral micro-interference RNA using multiple algorithms, relating to the field of biological detection. The method includes: removing adapters from an input sequence using multiple adapter removal algorithms, merging and deduplicating the resulting sequences to obtain an adapter-removed sequence; mapping the adapter-removed sequence to a ribosomal RNA database using multiple mapping algorithms in a cascaded manner, outputting a first incompletely mapped sequence; mapping the first incompletely mapped sequence to a host genome using the same mapping method, outputting a second incompletely mapped sequence; mapping the second incompletely mapped sequence to a viral genome using multiple mapping algorithms. If the second incompletely mapped sequence is mapped to the viral genome by any mapping algorithm with a mismatch number ≤ 1, it is determined to originate from a viral sequence. This invention significantly improves the efficiency and accuracy of mining viral micro-interference RNA from massive transcriptome data.

The application discloses a virus-host RNA sequence classification method and device based on AI, and relates to the field of biological detection.The method comprises the following steps: mapping preprocessed short read RNA sequences to a host genome twice, assembling short read RNA sequences which are not mapped to the host genome into continuous RNA sequences, and screening RNA sequences with a length greater than 1000bp from the continuous RNA sequences; and performing AI classification on the RNA sequences with a length greater than 1000bp to obtain virus RNA sequences.The application combines host filtering, rapid assembly and AI classification, can significantly reduce the calculation amount and hardware pressure, realizes efficient and accurate virus sequence classification, and can quickly distinguish unknown viruses.

The present disclosure concerns evaluation as to whether or not a nucleic acid fragment having a target gene had been accurately integrated into the host genome. A group of nucleic acid fragments comprising a nucleic acid fragment having a target gene is introduced into host cells, and host cells in which the target gene had been cleaved from the genome DNA by the action of a site-specific recombinase are selected.

The invention discloses a method for identifying viruses infected with dormant bacteria in fluvial sediments and application of the method. The invention relates to the technical field of microbiology and bioinformatics, and solves the problems that dead bacteria DNA interference cannot be effectively distinguished, a dormant host in an environmental sample is difficult to accurately recognize and the false positive rate of virus-host matching is relatively high in the prior art. The method comprises the following steps: carrying out propionium bromide azide treatment on a river sediment sample to obtain active microbial community DNA (Deoxyribonucleic Acid), and carrying out high-throughput sequencing; carrying out multi-module cooperative dormancy characteristic analysis on the assembled bacterial genome, and defining a dormancy host candidate genome; identifying a candidate virus sequence by adopting a triple cross validation mode; and extracting a CRISPR interval sequence in a dormant host genome, and comparing the CRISPR interval sequence with a candidate virus sequence to establish an infection relationship between the virus and the dormant host. According to the method, the false positive rate in the virus-host matching process can be reduced, and accurate identification of the virus infected with the dormant bacteria in a complex environment sample is realized.

The invention relates to the field of genomics, and discloses a genotype phenotype quantitative characterization method based on transposon mutation and high-throughput sequencing, which comprises the following steps: designing and constructing a recording transposon and a temperature-sensitive transposon plasmid; the method comprises the following steps: introducing a temperature-sensitive transposon plasmid into a host strain to obtain a transposon strain, inducing a recording transposon to be inserted into a host genome through temperature regulation and control, carrying out plasmid loss, carrying out amplification culture, and carrying out verification and evaluation to obtain a transposon mutant library which is verified to be qualified; and inoculating the transposon mutant library to a culture system corresponding to the target phenotype. The intracellular dynamic phenotypic difference is converted into a stable sequenced fusion transcript signal through fusion design of a recording type transposon and a phenotypic response type biosensor, construction of a mutant library mediated by temperature-sensitive transposon plasmids, collaborative sequencing of double sequencing libraries and correction of quantitative errors by a unique molecular identifier.

The invention discloses a circular RNA (Ribonucleic Acid) and an application of the circular RNA in a trichomonad pigeon vaccine. The coding element contained in the circular RNA can be used for coding the recombinant trichomonas pigeon AP33 or AP65 protein. The coding element has a sequence as shown in SEQ ID NO.1 or SEQ ID NO.2 or a conservative variant sequence of the sequence as shown in SEQ ID NO.1 or SEQ ID NO.2. The circular RNA can induce protein expression in an animal body and generate a high-level antibody, does not contain infectious insect species components, can be degraded into nucleotides in the body and cannot be integrated into a host genome when being applied to a trichomonad pigeon vaccine, has no risk to pigeons in use, can stimulate the pigeons to generate relatively strong immune responses including humoral immunity and cellular immunity, and can be used for preparing a vaccine for preventing and treating the pigeons. Meanwhile, the vaccine is high in stability, can be prepared on a large scale through a molecular technology, and is low in production cost.